Study type: In vivo/preclinical · Status: Citation identity verified

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4type 9 helper T cells and the VIP-VPAC2 signalling pathway.

Pharmaceutical biology · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

VIP: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.